with slides / As expected, the long-term results with the Taxus stent indicate that the stent has a durable biological effect that translates into reduced target lesion revascularization at two years.

The FDA said it is investigating problems with Boston Scientific's Taxus stent after a Michigan hospital suspended use of the devices. William Beaumont Hospital in Royal Oak stopped using the ...

The ISAR-SMART 3 study, conducted in people undergoing de novo stenting of a vessel <2.80 mm in diameter, has once again shown Cypher to have an edge over the Taxus stent. (Mehilli J et al. Eur ...

Key Results from the SPIRIT IV Trial. In the SPIRIT IV trial of 3,690 patients, XIENCE V demonstrated the following key results at two years: A 30 percent risk reduction in TLF compared to TAXUS ...